Currently, checkpoint inhibitors have shown a great potential in the treatment of multiple types of cancer [14, 15], among which antibodies blocking programmed death 1 (PD-1) and its ligand PD-L1 produced an impressively therapeutic effect in multiple malignancies [16–21]. Here, CD274 is linked to cancer.